Different challenges in eliminating HPV16 compared to other types: A modeling study

Journal of Infectious Diseases

Volumn 216, Issue 3, 2017, Pages 336-344

  Baussano, Iacopo ^a   Lazzarato, Fulvio ^a,b   Ronco, Guglielmo ^c   Lehtinen, Matti ^d,e   Dillner, Joakim ^e   Franceschi, Silvia ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^c Centre for Epidemiology and Prevention in Oncology in Piedmont   (Italy)

^d TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cervical cancer control; Cross protection; Herd effect; HPV vaccination

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BASIC REPRODUCTION NUMBER; CHILD; CROSS PROTECTION; DRUG EFFICACY; FEMALE; HERD IMMUNITY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 45; INFECTION CONTROL; INFECTION PREVENTION; MALE; NONHUMAN; PAPILLOMAVIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SEXUAL BEHAVIOR; UTERINE CERVIX CANCER; VACCINE IMMUNOGENICITY; VALIDATION PROCESS; VIRAL CLEARANCE; VIRUS TRANSMISSION; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOLOGY; ITALY; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PREVENTIVE HEALTH SERVICE; THEORETICAL MODEL; UTERINE CERVICAL NEOPLASMS; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; CROSS PROTECTION; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; IMMUNITY, HERD; IMMUNIZATION PROGRAMS; ITALY; MALE; MIDDLE AGED; MODELS, THEORETICAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 85029554165     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jix299     Document Type: Article

References (40)

1. Chow EP, Danielewski JA, Fehler G, et al. Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study. Lancet Infect Dis 2015; 15:1314-23.
2. Serrano B, de Sanjosé S, Tous S, et al. Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions. Eur J Cancer 2015; 51:1732-41.
3. Joura EA, Giuliano AR, Iversen OE, et al; Broad Spectrum HPV Vaccine Study. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015; 372:711-23.
4. Malagón T, Drolet M, Boily MC, et al. Cross-protective eficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:781-9.
5. Lehtinen M, Dillner J. Clinical trials of human papillomavirus vaccines and beyond. Nat Rev Clin Oncol 2013; 10:400-10.
6. Kreimer AR, Struyf F, Del Rosario-Raymundo MR, et al; Costa Rica Vaccine Trial Study Group Authors; PATRICIA Study Group Authors; HPV PATRICIA Principal Investigators/Co-Principal Investigator Collaborators; GSK Vaccines Clinical Study Support Group. Eficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials. Lancet Oncol 2015; 16:775-86.
7. Cameron RL, Kavanagh K, Pan J, et al. Human papillomavirus prevalence and herd immunity after introduction of vaccination program, Scotland, 2009-2013. Emerg Infect Dis 2016; 22:56-64.
8. Drolet M, Bénard É, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2015; 15:565-80.
9. Tabrizi SN, Brotherton JM, Kaldor JM, et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis 2014; 14:958-66.
10. Cuschieri K, Kavanagh K, Moore C, Bhatia R, Love J, Pollock KG. Impact of partial bivalent HPV vaccination on vaccine-type infection: a population-based analysis. Br J Cancer 2016; 114:1261-4.
11. Garnett G.P. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis 2005; 191(SUPPL. 1):S97-106.
12. Baussano I, Elfström KM, Lazzarato F, et al. Type-specific human papillomavirus biological features: validated model-based estimates. PLoS One 2013; 8:e81171.
13. Baussano I, Lazzarato F, Brisson M, Franceschi S. Human papillomavirus vaccination at a time of changing sexual behavior. Emerg Infect Dis 2016; 22:18-23.
14. Schiffman M, Doorbar J, Wentzensen N, et al. Carcinogenic human papillomavirus infection. Nat Rev Dis Primers 2016; 2:16086.
15. Guan P, Howell-Jones R, Li N, et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 2012; 131:2349-59.
16. Rositch AF, Koshiol J, Hudgens MG, et al. Patterns of persistent genital human papillomavirus infection among women worldwide: a literature review and meta-analysis. Int J Cancer 2013; 133:1271-85.
17. Signorelli C, Pasquarella C, Limina RM, et al. Third Italian national survey on knowledge, attitudes, and sexual behaviour in relation to HIV/AIDS risk and the role of health education campaigns. Eur J Public Health 2006; 16:498-504.
18. Ronco G, Giorgi-Rossi P, Carozzi F, et al; New Technologies for Cervical Cancer screening (NTCC) Working Group. Eficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010; 11:249-57.
19. Mesher D, Soldan K, Lehtinen M, et al. Population-level effects of human papillomavirus vaccination programs on infections with nonvaccine genotypes. Emerg Infect Dis 2016; 22:1732-40.
20. Safaeian M, Porras C, Pan Y, et al; CVT Group. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Phila) 2013; 6:1242-50.
21. Carozzi F, De Marco L, Gillio-Tos A, et al; NTCC Working Group. Age and geographic variability of human papillomavirus high-risk genotype distribution in a large unvaccinated population and of vaccination impact on HPV prevalence. J Clin Virol 2014; 60:257-63.
22. Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM; ALTS Group. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis 2007; 195:1582-9.
23. Rodríguez AC, Schiffman M, Herrero R, et al; Proyecto Epidemiológico Guanacaste Group. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 2008; 100:513-7.
24. Bogaards JA, Xiridou M, Coupé VM, Meijer CJ, Wallinga J, Berkhof J. Model-based estimation of viral transmissibility and infection-induced resistance from the age-dependent prevalence of infection for 14 high-risk types of human papillomavirus. Am J Epidemiol 2010; 171:817-25.
25. Vänskä S, Auranen K, Leino T, et al. Impact of vaccination on 14 high-risk HPV type infections: a mathematical modelling approach. PLoS One 2013; 8:e72088.
26. Beachler DC, Jenkins G, Safaeian M, Kreimer AR, Wentzensen N. Natural acquired immunity against subsequent genital human papillomavirus infection: a systematic review and meta-analysis. J Infect Dis 2016; 213:1444-54.
27. Vynnycky E, White RG. Sexually transmitted infections: an introduction to infectious disease modelling. Oxford, UK: Oxford University Press, 2010:223-81.
28. Baussano I, Franceschi S, Plummer M. Infection transmission and chronic disease models in the study of infection-associated cancers. Br J Cancer 2014; 110:7-11.
29. Burchell AN, Coutlée F, Tellier PP, Hanley J, Franco EL. Genital transmission of human papillomavirus in recently formed heterosexual couples. J Infect Dis 2011; 204:1723-9.
30. Schiffman M, Herrero R, Desalle R, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005; 337:76-84.
31. Brisson M, Van de Velde N, Boily MC. Different population-level vaccination effectiveness for HPV types 16, 18, 6 and 11. Sex Transm Infect 2011; 87:41-3.
32. Brisson M, van de Velde N, Franco EL, Drolet M, Boily MC. Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity. J Infect Dis 2011; 204:372-6.
33. Nsubuga RN, White RG, Mayanja BN, Shafer LA. Estimation of the HIV basic reproduction number in rural South West Uganda: 1991-2008. PLoS One 2014; 9:e83778.
34. Grassly NC, Fraser C, Garnett GP. Host immunity and synchronized epidemics of syphilis across the United States. Nature 2005; 433:417-21.
35. Brunham RC, Nagelkerke NJ, Plummer FA, Moses S. Estimating the basic reproductive rates of Neisseria gonorrhoeae and Chlamydia trachomatis: the implications of acquired immunity. Sex Transm Dis 1994; 21:353-6.
36. Anderson RM, May RM. Directly transmitted infections diseases: control by vaccination. Science 1982; 215:1053-60.
37. Brisson M, Bénard É, Drolet M, et al. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. Lancet Public Health 2016; 1:e8-17.
38. Lehtinen M, Paavonen J, Wheeler CM, et al; HPV PATRICIA Study Group. Overall eficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13:89-99.
39. Bruni L, Diaz M, Barrionuevo-Rosas L, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health 2016; 4:e453-63.
40. Wu T, Hu YM, Li J, et al. Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: a randomized controlled phase 2 clinical trial. Vaccine 2015; 33:3940-6.